• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

孕激素的体内代谢。V. 方案设计对女性醋酸甲羟孕酮代谢清除率和分布容积估计值的影响。

In vivo metabolism of progestins. V. The effect of protocol design on the estimated metabolic clearance rate and volume of distribution of medroxyprogesterone acetate in women.

作者信息

Gupta C, Osterman J, Santen R, Bardin C W

出版信息

J Clin Endocrinol Metab. 1979 May;48(5):816-20. doi: 10.1210/jcem-48-5-816.

DOI:10.1210/jcem-48-5-816
PMID:429526
Abstract

The metabolism of the synthetic progestin, [3H]medroxyprogesterone acetate (MPA), was studied in women using a single injection technique. Computer-implemented analysis was used to calculate the MCR (MCRMPA) and volume of distribution (VoMPA) from the steroid disappearance curve. The value of an objective curve-fitting technique was demonstrated. The effect of protocol design (number and frequency of samples) on these metabolic parameters was evaluated. The estimation of VoMPA was most sensitive to alterations of experimental design and biological variability, while MCR was less easily effected. The MCRMPA of 1668 +/- 146 (SEM) liters/day was lower than that for progesterone but higher than that of another synthetic steroid, dexamethasone. Treatment of women with MPA or aminoglutethimide, two drugs known to increase the rates of testosterone and dexamethasone metabolism, respectively, did not alter MCRMPA. From these observations we conclude 1) with the single injection technique it is difficult to estimate Vo of compounds such as MPA which are rapidly metabolized and 2) the MCRMPA was higher than expected and less susceptible to drug-induced changes than the clearance of other steroids.

摘要

采用单次注射技术,对使用合成孕激素[3H]醋酸甲羟孕酮(MPA)的女性的代谢情况进行了研究。利用计算机辅助分析,根据类固醇消失曲线计算MPA的代谢清除率(MCRMPA)和分布容积(VoMPA)。结果证明了一种客观曲线拟合技术的价值。评估了方案设计(样本数量和频率)对这些代谢参数的影响。VoMPA的估计对实验设计的改变和生物变异性最为敏感,而MCR则较不易受影响。MCRMPA为1668±146(标准误)升/天,低于孕酮,但高于另一种合成类固醇地塞米松。分别使用已知可提高睾酮和地塞米松代谢率的两种药物MPA或氨鲁米特治疗女性,并未改变MCRMPA。从这些观察结果我们得出结论:1)采用单次注射技术,难以估计像MPA这样快速代谢的化合物的Vo;2)MCRMPA高于预期,且与其他类固醇的清除率相比,对药物诱导的变化更不敏感。

相似文献

1
In vivo metabolism of progestins. V. The effect of protocol design on the estimated metabolic clearance rate and volume of distribution of medroxyprogesterone acetate in women.孕激素的体内代谢。V. 方案设计对女性醋酸甲羟孕酮代谢清除率和分布容积估计值的影响。
J Clin Endocrinol Metab. 1979 May;48(5):816-20. doi: 10.1210/jcem-48-5-816.
2
The in vivo metabolism of progestins. I. The metabolic clearance rates of progesterone and medroxyprogesterone acetate in the dog.
Endocrinology. 1976 Jul;99(1):108-13. doi: 10.1210/endo-99-1-108.
3
In vitro metabolism of progestins. III. The metabolic clearance rate of medroxyprogesterone acetate in monkeys.
Steroids. 1977 Mar;29(3):399-406. doi: 10.1016/0039-128x(77)90008-3.
4
The effects of diethylstilbestrol and medroxyprogesterone acetate on kinetics and production of testosterone and dihydrotestosterone in patients with prostatic carcinoma.己烯雌酚和醋酸甲羟孕酮对前列腺癌患者睾酮和双氢睾酮动力学及生成的影响。
J Clin Endocrinol Metab. 1976 Dec;43(6):1226-33. doi: 10.1210/jcem-43-6-1226.
5
The in vivo metabolism of progestins. IV. The metabolic clearance rate and plasma binding of 6alpha-methylpregn-4-ene-3, 20-dione in women.孕激素的体内代谢。IV. 6α-甲基孕-4-烯-3,20-二酮在女性体内的代谢清除率及血浆结合情况
Steroids. 1977 May;29(5):669-77. doi: 10.1016/0039-128x(77)90018-6.
6
Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.氨鲁米特对醋酸甲羟孕酮血浆水平的影响:及其与血清皮质醇的相关性。
Cancer Treat Rep. 1985 Jan;69(1):85-90.
7
Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.氨鲁米特对晚期乳腺癌绝经后患者醋酸甲羟孕酮和醋酸甲地孕酮代谢的影响。
Cancer Chemother Pharmacol. 1990;27(2):101-5. doi: 10.1007/BF00689091.
8
Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer.醋酸甲羟孕酮在晚期乳腺癌患者中的药代动力学与代谢
J Steroid Biochem. 1988 Oct;31(4A):437-41. doi: 10.1016/0022-4731(88)90312-3.
9
[Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
Onkologie. 1982 Aug;5 Suppl:34-41.
10
Modulation of aromatase activity in human endometrial stromal cells by steroids, tamoxifen and RU 486.类固醇、他莫昔芬和RU 486对人子宫内膜基质细胞中芳香化酶活性的调节作用。
Endocrinology. 1986 Apr;118(4):1312-8. doi: 10.1210/endo-118-4-1312.

引用本文的文献

1
Management of epilepsy in women.女性癫痫的管理
Postgrad Med J. 2005 May;81(955):278-85. doi: 10.1136/pgmj.2004.030221.
2
Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.在使用氨鲁米特抑制雌激素治疗转移性乳腺癌期间雄激素分泌的保留情况。
J Clin Invest. 1980 Mar;65(3):602-12. doi: 10.1172/JCI109705.
3
Effect of medroxyprogesterone acetate on serum levels of LH, FSH, cortisol, and estrone in patients with endometrial carcinoma.
Arch Gynecol. 1981;230(3):205-11. doi: 10.1007/BF02111804.
4
Single-dose and steady-state pharmacokinetics of aminoglutethimide.氨鲁米特的单剂量和稳态药代动力学
Clin Pharmacokinet. 1985 Jul-Aug;10(4):353-64. doi: 10.2165/00003088-198510040-00005.
5
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.氨鲁米特作为乳腺癌内分泌治疗的作用机制
Drugs. 1988 Jun;35(6):685-710. doi: 10.2165/00003495-198835060-00005.
6
Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.醋酸甲羟孕酮制剂生物利用度差异的临床意义
Clin Pharmacokinet. 1989 Mar;16(3):129-33. doi: 10.2165/00003088-198916030-00001.
7
Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.氨鲁米特对晚期乳腺癌绝经后患者醋酸甲羟孕酮和醋酸甲地孕酮代谢的影响。
Cancer Chemother Pharmacol. 1990;27(2):101-5. doi: 10.1007/BF00689091.
8
Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.晚期乳腺癌中使用的内分泌药物的临床药代动力学
Clin Pharmacokinet. 1992 May;22(5):327-58. doi: 10.2165/00003088-199222050-00002.